Somerville Kurt F Has Decreased Its Gilead Sciences (GILD) Holding; LCNB Has 2.4 Sentiment

February 25, 2018 - By Migdalia James

Somerville Kurt F decreased Gilead Sciences (GILD) stake by 14.57% reported in 2017Q3 SEC filing. Somerville Kurt F sold 5,135 shares as Gilead Sciences (GILD)’s stock declined 8.05%. The Somerville Kurt F holds 30,117 shares with $2.44M value, down from 35,252 last quarter. Gilead Sciences now has $105.69 billion valuation. The stock increased 1.90% or $1.51 during the last trading session, reaching $80.91. About 5.63 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since February 25, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

LCNB Corp. operates as the financial holding firm for LCNB National Bank that provides commercial and personal banking services in Ohio. The company has market cap of $188.43 million. The Company’s deposit products include checking, NOW, savings, Christmas and vacation club, money market deposit, lifetime checking, and individual retirement accounts, as well as certificates of deposit. It has a 14.57 P/E ratio. The companyÂ’s loan portfolio comprises commercial and industrial, commercial and residential real estate, agricultural, construction, small business administration, and residential mortgage loans.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences had 125 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, September 14 by Credit Suisse. The rating was maintained by Cowen & Co with “Buy” on Monday, September 21. Bank of America maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, October 4 with “Neutral” rating. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Outperform” rating by Credit Suisse on Wednesday, January 20. Jefferies maintained the shares of GILD in report on Wednesday, October 5 with “Buy” rating. Piper Jaffray maintained Gilead Sciences, Inc. (NASDAQ:GILD) rating on Friday, July 24. Piper Jaffray has “Overweight” rating and $131 target. Piper Jaffray upgraded the stock to “Overweight” rating in Thursday, November 5 report. Jefferies maintained the shares of GILD in report on Tuesday, October 25 with “Buy” rating. Cowen & Co maintained it with “Buy” rating and $90.0 target in Wednesday, October 18 report. The firm has “Buy” rating given on Tuesday, February 6 by Maxim Group.

Since August 30, 2017, it had 0 insider purchases, and 15 insider sales for $56.94 million activity. Alton Gregg H sold $1.11M worth of stock. MARTIN JOHN C sold $3.68 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Tuesday, January 2. Meyers James R had sold 100,000 shares worth $8.02M on Tuesday, January 16. $4.68M worth of stock was sold by WILSON GAYLE E on Friday, February 9. 51,820 shares were sold by Washington Robin L, worth $4.40 million.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1. They expect $1.59 earnings per share, down 27.73% or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.08B for 12.72 P/E if the $1.59 EPS becomes a reality. After $1.60 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63% negative EPS growth.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It is positive, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Moreover, Gamble Jones Inv Counsel has 0.16% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Brighton Jones Lc has 3,468 shares. Whittier accumulated 169,995 shares. Fort LP holds 4.88% or 244,713 shares in its portfolio. 517,768 are held by Toronto Dominion Savings Bank. Bluestein R H And holds 0.01% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 2,564 shares. Asset Mgmt One Ltd stated it has 2.10 million shares or 0.4% of all its holdings. Stillwater Mgmt Ltd Liability invested in 1.38% or 37,351 shares. California Public Employees Retirement Sys invested in 0.39% or 3.27M shares. Finemark Natl Bankshares invested in 13,246 shares or 0.07% of the stock. Rothschild Asset Mngmt stated it has 840,155 shares. Denali Advsrs Ltd Liability holds 1.87% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 139,577 shares. Murphy Capital Mngmt Inc has invested 0.1% in Gilead Sciences, Inc. (NASDAQ:GILD). Cadence Cap Management Limited Liability Co holds 0.85% or 168,324 shares. Cutter Com Brokerage Incorporated holds 0.69% or 21,495 shares in its portfolio.

Since January 1, 0001, it had 1 buying transaction, and 3 sales for $92,778 activity.

Analysts await LCNB Corp. (NASDAQ:LCNB) to report earnings on April, 18. They expect $0.38 earnings per share, up 18.75% or $0.06 from last year’s $0.32 per share. LCNB’s profit will be $3.81M for 12.37 P/E if the $0.38 EPS becomes a reality. After $0.34 actual earnings per share reported by LCNB Corp. for the previous quarter, Wall Street now forecasts 11.76% EPS growth.

The stock increased 1.08% or $0.2 during the last trading session, reaching $18.8. About 16,613 shares traded or 46.41% up from the average. LCNB Corp. (LCNB) has risen 17.18% since February 25, 2017 and is uptrending. It has outperformed by 0.48% the S&P500.

American Financial Group Inc holds 0.24% of its portfolio in LCNB Corp. for 109,285 shares. Kennedy Capital Management Inc. owns 503,798 shares or 0.19% of their US portfolio. Moreover, Cutter & Co Brokerage Inc. has 0.16% invested in the company for 19,134 shares. The California-based Saratoga Research & Investment Management has invested 0.05% in the stock. Johnson Investment Counsel Inc, a Ohio-based fund reported 41,124 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Migdalia James

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: